Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
T. T. Zhang
R. M. Wang
Z. Yang
G. B. Chen
机构：
[1] The First People’s Hospital of Shangqiu,Department of Oncology
[2] The First People’s Hospital of Shangqiu,Department of General Surgery
[3] The First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Non-small-cell lung cancer; EGFR-TKIs; Molecular targeted agents; Angiogenesis inhibitors; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 581
页数：5
相关论文
共 50 条
  • [41] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
    Chen, Dan
    Song, Zhengbo
    Cheng, Guoping
    ONCOTARGETS AND THERAPY, 2016, 9 : 4181 - 4186
  • [42] Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials
    Yu, Shuhan
    Xu, Qini
    Yuan, Yun
    Li, Xuyuan
    Cai, Haoquan
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 1927 - 1934
  • [43] Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
    Zhao, Ning
    Zhang, Xu-chao
    Yan, Hong-hong
    Yang, Jin-ji
    Wu, Yi-long
    LUNG CANCER, 2014, 85 (01) : 66 - 73
  • [44] Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
    Yi, Xiao-Fang
    Song, Jun
    Gao, Ruo-Lin
    Sun, Li
    Wu, Zhi-Xuan
    Zhang, Shu-Ling
    Huang, Le-Tian
    Ma, Jie-Tao
    Han, Cheng-Bo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
    Yu, Yinan
    Zhao, Jianguo
    Xu, Jiaona
    Bai, Rui
    Gu, Zewei
    Chen, Xialin
    Wang, Jianfang
    Jin, Xueying
    Gu, Gaoyang
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1889 - 1916
  • [46] Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
    Yinan Yu
    Jianguo Zhao
    Jiaona Xu
    Rui Bai
    Zewei Gu
    Xialin Chen
    Jianfang Wang
    Xueying Jin
    Gaoyang Gu
    Current Treatment Options in Oncology, 2023, 24 : 1935 - 1947
  • [47] The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials
    Tian, Rong-Hua
    Wu, Xia
    Liu, Xia
    Yang, Jin-Wang
    Ji, Hua-Liang
    Yan, Yong-Jin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 571 - 575
  • [48] Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis
    Yu, Guo-Can
    Yang, Jun
    Ye, Bo
    Xu, Li-Liang
    Li, Xiao-Yuan
    Zheng, Guan-Rong
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 7659 - 7670
  • [49] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [50] LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
    Wu, Yahua
    Du, Bin
    Lv, Chengliu
    Ji, Xiaohui
    Lai, Jinhuo
    ANNALS OF MEDICINE, 2023, 55 (02)
12345